BMS upgrades Evotec neurology alliance, now worth up to $4bn

Bristol-Myers Squibb has expanded a long-running alliance with Evotec once again, paying another $50 million upfront to deepen their collaboration on drugs to treat neurod

Boehringer takes on antimicrobial resistance with Evotec, bi...

A Franco-German joint venture company – Aurobac Therapeutics – has been formed to try to tackle the rising threat of antimicrobial resistant (AMR) infections.

BMS pays $200m to expand Evotec alliance on protein degrader...

Bristol-Myers Squibb's Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation.

Vifor joins forces with Evotec on kidney disease joint ventu...

Evotec announces potential $850m R&D partnership with Takeda

Germany’s Evotec has announced another high-profile R&D partnership with big pharma, beginning a multi-year R&D partnership with Takeda, focusing on discovering small molecule drugs

Evotec begins new Oxford Uni digital health partnership

Germany’s Evotec has begun a new strategic partnership with the British AI tech company Sensyne Health and Oxford University to translate research into new companies working on digital heal